In December 2024, Daiichi Sankyo was selected as a pharmaceutical sector constituent of the Dow Jones Sustainability Indices Asia Pacific Index (DJSI Asia Pacific), a leading global ESG index.
We will continue to aim to realize our purpose of "contribute to the enrichment of quality of life around the world", to continuously improve our corporate value, and to become a company that is trusted by our stakeholders.